SCHEDULE 13G/A: Armistice Capital and Steven Boyd Disclose 9.99% Passive Stake in MAINZ BIOMED N.V.

Armistice Capital, LLC and Steven Boyd have filed an amended Schedule 13G, revealing a shared beneficial ownership of 9.99% of MAINZ BIOMED N.V.'s Ordinary Shares.

Summary

• Armistice Capital, LLC and Steven Boyd, collectively referred to as the "Reporting Persons," have filed an Amendment No. 1 to Schedule 13G regarding their beneficial ownership in MAINZ BIOMED N.V.
• The filing indicates that the Reporting Persons beneficially own an aggregate of 324,821 Ordinary Shares of MAINZ BIOMED N.V., representing 9.99% of the class.
• Both Armistice Capital, LLC and Steven Boyd share voting and dispositive power over all 324,821 shares.
• The shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.
• Armistice Capital, LLC is identified as an investment adviser, and Steven Boyd as a control person.
• The Master Fund, a Cayman Islands exempted company and an investment advisory client of Armistice Capital, has the right to receive dividends and proceeds from the sale of these securities.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing disclosing beneficial ownership and does not contain information that would significantly alter sentiment, beyond confirming a significant passive institutional stake.

Positives

• A significant institutional investor, Armistice Capital, LLC, and its managing member, Steven Boyd, hold a substantial stake of 9.99% in MAINZ BIOMED N.V., indicating confidence in the company.
• The filing is a Schedule 13G, signifying a passive investment intent, which typically means the investor is not seeking to influence or change control of the company.

Future Outlook

This document does not contain any forward-looking statements or guidance.

Management Comments

• "The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect."

Industry Context

This filing indicates continued or new institutional interest in MAINZ BIOMED N.V., a company likely operating in the biotechnology or medical diagnostics sector given its name. Such disclosures are common for publicly traded companies as institutional investors adjust their holdings.

Related Party Transactions

• The Master Fund, a Cayman Islands exempted company that is an investment advisory client of Armistice Capital, has the right to receive dividends from, or the proceeds from the sale of, the reported securities.

Stakeholder Impact

• Shareholders: Provides transparency on significant institutional ownership, potentially signaling confidence from a major investor.
• Management: Awareness of a large passive shareholder, though not one seeking control.

Key Dates

Keywords

MAINZ BIOMED N.V., Armistice Capital, Steven Boyd, Schedule 13G, Beneficial Ownership, Ordinary Shares, Institutional Investment, Passive Stake, SEC Filing, Biotech